Breaking Finance News

Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been upgraded to Hold in a statement by ValuEngine earlier today.

ValuEngine has upgraded Portola Pharmaceuticals Inc (NASDAQ:PTLA) to Hold in a statement released on Friday June 02, 2017.

On 3/20/2017, Vetr Inc. released a statement for Portola Pharmaceuticals Inc (NASDAQ:PTLA) bumped up the target price from $0.00 to $45.18 that suggested an upside of 0.12%.

Boasting a price of $37.38, Portola Pharmaceuticals Inc (NASDAQ:PTLA) traded 0.36% higher on the day. With the last stock price close down 1.64% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Portola Pharmaceuticals Inc has recorded a 50-day average of $54.34 and a two hundred day average of $49.83. Volume of trade was down over the average, with 559,153 shares of PTLA changing hands under the typical 947,037

Recent Performance Chart

Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals Inc has 52 week low of $15.68 and a 52 week high of $67.10 and has a market cap of $0.

Also covering Portola Pharmaceuticals Inc's price target, a total of 5 analysts have released a research note on the company. The average stock price target is $47.80 with 2 brokers rating the company a strong buy, four brokerages rating the company a buy, 0 firms rating the stock a hold, 0 firms rating the company a underperform, and lastly zero equity analysts rating the company a sell.

More About Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.